«YTD, IMV shares have generated strong returns of 125 %, with 37 % of this generated since our Top Pick update, and we see strong price appreciation potential on forthcoming DPX - Survivac clinical updates as described above, independent of any new pipeline advances that Immunovaccine may
undertake during our forecast period.